Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice is a research paper published in Ophthalmology (2020). On theSindex it has a DataRank of 0. It has been cited 73 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Yale-Mayo Clinic Center
Grant: U01FD005938
Agency for Healthcare Research and Quality
Grant: U19HS024075
Agency for Healthcare Research and Quality
Grant: R01HS025164
Agency for Healthcare Research and Quality
Grant: R01HS025402
Agency for Healthcare Research and Quality
Grant: R03HS025517
Agency for Healthcare Research and Quality
Grant: K12HS026379
National Institutes of Health
Grant: R56HL130496
National Institutes of Health
Grant: R01HL131535
National Institutes of Health
Grant: R01AG062823
National Heart, Lung, and Blood Institute
National Institute for Aging
Kern Center
Centers of Medicare and Medicaid Innovation under the Transforming Clinical Practice Initiative
Mayo Clinic
National Science Foundation
Patient Centered Outcomes Research Institute
FWCI
6.60
Citation Percentile
1.0%
Influential Citations
2
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals